ARTICLE | Clinical News
Cotellic cobimetinib regulatory update
October 5, 2015 7:00 AM UTC
EMA’s CHMP recommended approval of Cotellic cobimetinib in combination with Zelboraf vemurafenib to treat adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The companies expect a decision by year end. ...